Navigation Links
Older blacks and Latinos still lag whites in controlling diabetes
Date:9/24/2007

the strongest influence on racial and ethnic differences in A1C levels were medication adherence (especially among African Americans) and emotional distress related to diabetes (especially among Latinos). African Americans reported more barriers to taking their medications, and less adherence to their medication, than the other groups. Meanwhile, Latinos reported much higher levels of distress related to their diabetes than other groups.

Even so, all the factors examined in the analyses that might account for the observed racial and ethnic disparities in glycemic control accounted for only 14 percent of the African American-white disparity, and 19 percent of the Latino-white disparity, in blood sugar control. Meanwhile, differences in income and education level two factors long hypothesized to be key determinants of worse diabetes outcomes did not explain the glucose control differences, once the other factors were included in the analyses.

The authors conclude that additional factors not assessed in the study, such as genetics, stress levels and other environmental factors, intensity of medication regimens, and the generosity of patients prescription drug insurance coverage must account for a large part of the picture.

Medication adherence was one of the strongest predictors of glucose control across the board, says Heisler. This reinforces that by targeting barriers to medication adherence such as patient-doctor communication about medications, patient trust in health systems, patient confidence that medication actually helps, cost barriers, and other barriers that African Americans disproportionately face we can make a difference.

"Diabetes is one of the most important health challenges faced by Americans and American society today," notes Richard Suzman, Ph.D., director of behavioral and social research at the National Institute on Aging. "These results illuminate some of the behavioral and other issues associated wit
'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Older men father schizophrenics
2. Creatine Helps Strengthen Older Men
3. Older Men Surviving Coronary Bypasses
4. Acoustic neuroma in older patients to be treated
5. Quality of lives of older people
6. Pregnancy shouldnt be dissuaded in older age
7. Cholesterol-lowering therapy benefits older people also
8. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
9. Older womens heart health depends on location of fat
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Frailty in Older Women may be due to Chronic Infection
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Illness often undiscovered and undertreated among the uninsured 3A Harvard study 59784 1Illness often undiscovered and undertreated among the uninsured 3A Harvard study 59784 2FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 1FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 2FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 3FDA approves GlaxoSmithKlines VOTRIENT 28TM 29 for advanced renal cell cancer 5578 4Checkered history of mother and daughter cells explains cell cycle differences 10424 1Checkered history of mother and daughter cells explains cell cycle differences 10424 2Checkered history of mother and daughter cells explains cell cycle differences 10424 3